{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:37:47Z","timestamp":1789958267591,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.urology.2013.08.074","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T12:30:39Z","timestamp":1384259439000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases"],"prefix":"10.1016","volume":"83","author":[{"given":"Alev","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Danenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Schuckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek K.","family":"Pinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2013.08.074_bib1","first-page":"277","article-title":"Cancer Statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2013.08.074_bib2","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1158\/1055-9965.EPI-08-0456","article-title":"Risk factors for squamous cell carcinoma of the penis \u2013 population-based case-control study in Denmark","volume":"17","author":"Madsen","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urology.2013.08.074_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-008-0310-z","article-title":"Multimodality therapy in penile cancer: when and which treatments?","volume":"27","author":"Pagliaro","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2013.08.074_bib4","first-page":"1823","article-title":"Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study","volume":"161","author":"Haas","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.08.074_bib5","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3747\/co.v17i1.471","article-title":"EGFR overexpression in squamous cell carcinoma of the penis","volume":"17","author":"Lavens","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardello","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.urology.2013.08.074_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e15022","article-title":"Epidermal growth factor receptor (EGFR) targeted therapy in advanced metastatic squamous cell carcinoma (AMSCC) of the penis: updates and molecular analyses","volume":"28","author":"Carthon","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib9","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-08-1056","article-title":"Her-2 gene amplification, Her-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer","volume":"14","author":"Press","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2013.08.074_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/jco.2007.25.18_suppl.14045","article-title":"Epidermal growth factor receptor expression in and targeted therapy for metastatic squamous cell carcinoma of the penis","volume":"25","author":"Pagliaro","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000315432","article-title":"Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report","volume":"85","author":"Zhu","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2013.08.074_bib12","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1200\/JCO.2011.34.8367","article-title":"Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis","volume":"29","author":"Necchi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CAD.0b013e328350ead7","article-title":"Combination of docetaxel and cetuximab for penile cancer: a case report and literature review","volume":"23","author":"Rescigno","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.urology.2013.08.074_bib14","doi-asserted-by":"crossref","first-page":"778e11","DOI":"10.1016\/j.urology.2003.12.026","article-title":"Major tumor regression after pacliatxel and carboplatin polychemotherapy in a patient with advanced penile cancer","volume":"63","author":"Joerger","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urology.2013.08.074_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.urolonc.2007.10.015","article-title":"Cisplatin and gemcitabine in the management of metastatic penile cancer","volume":"27","author":"Power","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2013.0076","article-title":"Current concepts in penile cancer","volume":"11","author":"Spiess","year":"2013","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.urology.2013.08.074_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0090-4295(93)90273-D","article-title":"Penile cancer chemotherapy: twelve years\u2019 experience at Institut Gustave-Roussy","volume":"42","author":"Kattan","year":"1993","journal-title":"Urol"},{"key":"10.1016\/j.urology.2013.08.074_bib18","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase II study","volume":"60","author":"DiLorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2013.08.074_bib19","doi-asserted-by":"crossref","first-page":"e62175","DOI":"10.1371\/journal.pone.0062175","article-title":"Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma","volume":"8","author":"Gou","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.urology.2013.08.074_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.urology.2013.08.074_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib22","series-title":"EGFR, TS, and ERCC1 expression in penile squamous cancer (PSC). Poster presentation at the ASCO GU","author":"Dorff","year":"2011"},{"key":"10.1016\/j.urology.2013.08.074_bib23","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to eroltinib in national cancer institute of\u00a0Canada clinical trials group study br.21","volume":"26","author":"Zhu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib24","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib25","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2013.08.074_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-154-1-201101040-00006","article-title":"Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer","volume":"154","author":"Dahabreh","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urology.2013.08.074_bib27","series-title":"BRAF and KRAS mutations in penile cancer and their correlation with clinical features. Poster presentation at the ASCO GU","author":"Valverde","year":"2011"},{"key":"10.1016\/j.urology.2013.08.074_bib28","first-page":"3988","article-title":"Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma","volume":"7","author":"Almadori","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2013.08.074_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000050613","article-title":"Abnormal expression of epidermal growth factor receptor and c-erb-B2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis","volume":"22","author":"Ngan","year":"2001","journal-title":"Tumor Biol"},{"key":"10.1016\/j.urology.2013.08.074_bib30","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429513012442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429513012442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:57:09Z","timestamp":1758765429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429513012442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0090429513012442"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2013.08.074","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2013.08.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}